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abstract
Diagnosing cancer earlier can enable timely treatment and optimize outcomes. Worldwide, national cancer
control plans increasingly encompass early diagnosis programs for symptomatic patients, commonly comprising
awareness campaigns to encourage prompt help-seeking for possible cancer symptoms and health system
policies to support prompt diagnostic assessment and access to treatment. By their nature, early diagnosis
programs involve complex public health interventions aiming to address unmet health needs by acting on
patient, clinical, and system factors. However, there is uncertainty regarding how to optimize the design and
evaluation of such interventions. We propose that decisions about early diagnosis programs should consider four
interrelated components: first, the conduct of a needs assessment (based on cancer-site–specific statistics) to
identify the cancers that may benefit most from early diagnosis in the target population; second, the con-
sideration of symptom epidemiology to inform prioritization within an intervention; third, the identification of
factors influencing prompt help-seeking at individual and system level to support the design and evaluation of
interventions; and finally, the evaluation of factors influencing the health systems’ capacity to promptly assess
patients. This conceptual framework can be used by public health researchers and policy makers to identify the
greatest evidence gaps and guide the design and evaluation of local early diagnosis programs as part of broader
cancer control strategies.
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INTRODUCTION
Cancer control is a global health priority.1 In high-
income countries (HICs), cancer incidence is increas-
ing with other noncommunicable diseases, whereas in
lower- and middle-income countries (LMICs), there is
often a concordant double burden of communicable
diseases.2 Furthermore, prolonged time to diagnosis
and treatment is disproportionately experienced by
poorer individuals, contributing to disparities in cancer
outcomes within and between countries.1,3
Diagnosing symptomatic cancer earlier is a feasible
and cost-effective strategy4,5 that can contribute
to better clinical outcomes6-9 and improve patient
experience.10-12 Effective asymptomatic detection is
currently only available for a few cancers, and even in
countries with established population-based screening
programs, the majority of patients with cancer are
diagnosed following symptomatic presentation.3,13,14
Furthermore, in low-resource settings where screen-
ing programs are not available or feasible,15-17 early
diagnosis (also known as clinical downstaging) strat-
egies can support their introduction by improving
clinical pathways and building diagnostic capacity.18
Early diagnosis programs consist of supporting prompt
help-seeking among symptomatic individuals and/or
enabling timely access to diagnosis and treatment.1
Public education campaigns aiming to raise aware-
ness of cancer and its symptoms and signs among the
general population have been conducted in both HICs
and LMICs (Box 1)19,26,29-33, whereas fast-track path-
ways and clinical guidelines aiming to expedite the
investigation, diagnosis, and treatment of symptomatic
individuals have been introduced in HICs including the
United Kingdom, Denmark, New Zealand, and Spain
(Box 2).39,45-48
THE NEED FOR A FRAMEWORK TO GUIDE
DECISION MAKING
The timeliness of cancer diagnosis and treatment in
symptomatic patients has been conceptualized as a
series of intervals starting from symptom onset.12,49-51
Building on these theoretical foundations, it is impor-
tant to consider how early diagnosis evidence can be
translated into interventions.
Early diagnosis programs represent complex interven-
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behavior and often interdependent health system
factors.52,53 The majority of early diagnosis initiatives are
implemented as natural experiments,22,54,55 compounding
the difficulties in measuring impact and effectiveness.
We propose a framework to aid the design and evaluation
of early diagnosis programs (Fig 1). It draws on existing
literature from HIC and LMIC settings, augmented by the
expert opinions of the international group of authors.
The framework comprises four components: first, the
conduct of a needs assessment (based on cancer-
site–specific statistics) to identify the cancers that may
benefit most from early diagnosis in the target pop-
ulation; second, the consideration of symptom epide-
miology to inform prioritization within an intervention;
third, the identification of factors influencing prompt
help-seeking at individual and system level to support
the design and evaluation of interventions; and finally,
the appraisal of factors influencing the health systems’
capacity to promptly assess patients.
CANCER NEEDS ASSESSMENT
Local or contextualized epidemiological knowledge about
the incidence, mortality, and survival associated
with different cancers in a given setting can inform the
prioritization of cancer types when designing an early di-
agnosis program. These considerations should ideally be
based on high-quality population-based cancer regis-
tries and mortality data, although this is conditional on
cancer registry infrastructure.56 Cancer-specific incidence
alone may be instructive, whereas other characteristics
such as the frequency and distribution of advanced stage
at diagnosis among cases, site- and stage-specific
survival statistics, and existing levels of awareness among
CONTEXT
Key Objective
Prompt diagnosis and treatment of symptomatic patients can improve cancer outcomes, but this depends on many individual
and health system factors. What are the key considerations that need to be taken into account when developing early
diagnosis programs?
Knowledge Generated
The design, implementation, and evaluation of early diagnosis programs should be informed by the assessment of population-
specific health needs; the epidemiology of symptoms of possible cancer; and the consideration of individual and health
system factors influencing both timely help-seeking for new symptoms and timely investigation and treatment. Framed
within the broader evidence base, case studies from the United Kingdom, Denmark, Malaysia, and Zambia are used to
illustrate existing early diagnosis activities.
Relevance
This framework can help identify population-specific evidence gaps in early cancer diagnosis research and guide the design
and evaluation of early diagnosis programs across the globe.
BOX 1. EXAMPLES OF SYMPTOM AWARENESS CAMPAIGN DESIGN AND EVALUATION IN ENGLAND AND MALAYSIA
In England, national Be Clear on Cancer campaigns were developed in 2012 through the partnership of governmental
agencies and Cancer Research UK, a charity. Nationwide campaigns designed to target individuals of age 50+ years have
been conducted for colorectal, lung, breast, bladder, kidney, and esophagogastric cancers.19,20,25 The visual and linguistic
components of the campaign were designed to engage individuals from lower socioeconomic groups and alleviate possible
concerns about bothering the doctor.21 Campaign evaluations have found increasing levels of awareness and frequency of
help-seeking for some symptoms and increased referrals and use of investigations for suspected cancer by primary care
physicians although evidence of improvement in stage at diagnosis and survival is limited.22-25
In Malaysia, breast and colorectal cancers were the focus of Be Cancer Alert, a culturally sensitive mass media campaign led
by a multisector partnership of researchers from Malaysia and the United Kingdom.26 The campaign focused on breast and
colorectal cancers because of the high prevalence of these cancers in Malaysia, and the design was driven by evidence
suggesting low awareness of the alarm symptoms of breast and colorectal cancer among members of the public as well as
negative attitudes and beliefs regarding cancer. The campaign’s logic model takes contextual factors into account, including
differences in knowledge and cultural norms between the main ethnic groups in Malaysia (Malays, Chinese, and Indian) and
health and media literacy.27 Recently published findings indicate improvements in symptom awareness at follow-up across
ethnic and social strata although, in common with the English experience, evidence of improvements in downstream
outcomes was less clear.28
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the general population can further contribute to the prior-
itization of cancer types to be targeted by early diagnosis
programs.12 In the absence of such data, as in many LMICs,
data collectionmay be necessary to gauge capacity for early
diagnosis; local- or regional-level statistics from hospital-
based cancer registries or other sources could be useful.
Contextual factors such as stakeholder views, socio-
cultural and political factors, and health system factors
such as access and affordability of cancer treatment and
healthcare providers will also influence how cancers are
ranked by the need for early diagnosis57 and may often be
stronger drivers for action particularly in settings where data
capture and collection are difficult.
SYMPTOM EPIDEMIOLOGY
Early diagnosis interventions are, by their nature, centered
on specific presenting symptoms of cancer. Accordingly,
understanding symptom epidemiology, that is, population-
level evidence regarding the nature and frequency of pre-
senting symptoms, can help the targeting of interventions.58
Evidence on presenting symptoms may be collected ret-
rospectively through patient recall or extracted from health
records where information is captured prospectively dur-
ing consultations. Self-report-based approaches provide
firsthand insight, although may be associated with recall
bias (because of the retrospective nature of recalling
BOX 2. FAST-TRACK PATHWAYS FOR SUSPECTED CANCER IN ENGLAND AND DENMARK
For most common cancers, cancer survival in England (United Kingdom) and Denmark is comparatively poor to other high-
income countries.34,35 This has stimulated the relative prioritization of early diagnosis as part of cancer control measures in
these countries.
Fast-track (2-week-wait) referral pathways from primary care to specialist assessment were introduced in England in 1999/
2000.36 In parallel, national clinical guidelines have been developed to support the pathways: certain red-flag alarm symptoms
are recommended for referral based on their positive predictive value for cancer.37 Around 2.4 million symptomatic individuals
are referred using this pathway annually, of which 93% occur within 14 days and around 8% are subsequently diagnosed with
cancer.36,38 For individuals subsequently diagnosed with cancer (through any route), national targets for the treatment
interval (time from decision to treat to first treatment) are set at a maximum of 31 days.38 In Denmark, a similar fast-track
referral system was introduced in 2008 called the Cancer Patient Pathway.39
Evaluating the impact of the fast-track pathways is challenging because of the waiting time paradox, whereby indi-
viduals with more severe and acute onset symptoms are diagnosed quickly but have poorer survival compared with
patients who experience longer time to diagnosis.6,7 Accounting for this phenomenon, the introduction of fast-track
pathways has been associated with improvements in cancer survival.40,41 Primary care practices with higher usage of
the 2-week-wait referral pathway have been associated with lower mortality in England.42 Furthermore, increasing use
of the 2-week-wait pathway over time has been associated with decreasing proportions of patients diagnosed with
cancer as an emergency,43 a marker of poor prognosis.44
Contextual factors (sociocultural, economic, political)
Cancer needs assessment
Which cancers would benefit most from
early diagnosis?
Factors influencing prompt help-seeking
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FIG 1. Conceptual framework for the
design and evaluation of early diag-
nosis programs for cancer.
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experienced symptoms) and survival bias (where patients
who are the sickest are less likely to be included). In
comparison, prospective health record studies allow for the
study of much larger populations, but incomplete symp-
tom elicitation and recording may introduce other biases.59
The latter may be used to derive the positive predictive
value (PPV) of symptoms for cancer, which expresses the
probability that following presentation with a symptom, that
individual will be diagnosed with cancer.
There is a large body of literature on symptom-specific PPVs
for cancer based on primary care electronic health record
studies in England (see Table 1 for selected examples).60-75
This evidence informed the development of an explicit PPV
threshold of 3% used to prioritize symptoms for urgent in-
vestigation and fast-track 2-week-wait referral in England.36,37
Currently, there is no available evidence, and no biological
reason, to suggest that the nature of cancer symptoms or
their relative frequency at presentation may vary between
different countries, although psychosocial and health
system factors could influence how symptoms are
reported.76,77 The English studies indicate that PPVs in-
crease with age and are higher among men; other differ-
ences in demographic factors, pre-existing conditions
(morbidities), and symptom prevalence could lead to
variation in symptom PPVs across populations, for exam-
ple, the PPV of respiratory symptoms for lung cancer in
communities with high tuberculosis prevalence. As LMICs
develop electronic medical records, examining country-
specific symptom prevalence and PPVs will be necessary.
Nevertheless, around 50% of patients with cancer present
with nonspecific or vague symptoms that are associated
with much lower PPVs for cancer.78 In Denmark, patients
with nonspecific symptoms (eg, unexplained weight loss,
fatigue, and abdominal pain) are referred to multidisci-
plinary clinics where a battery of investigations (blood and
urine tests and diagnostic imaging) can be conducted
rapidly.39 Similarly designed clinics have been introduced
in the United Kingdom to accommodate individuals who
present with nonalarm symptoms.79-83
Evidence regarding pre-existing levels of symptom aware-
ness and symptom-specific measures of diagnostic time-
liness could guide the selection of symptoms in early
diagnosis programs. Validated measures including the
Cancer Awareness Measure,84,85 the Awareness and Beliefs
about Cancer measure,86 and region-specific adaptations
TABLE 1. Selected Studies From a Convenience Sample That Estimate Positive Predictive Value of Common Alarm Symptoms for Cancer in Patients
Consulting in Primary Care Based on the English Population
Symptom Predictive Value of Single Symptoms for a Specific Cancer Site* Reference
Breast lump 25% for breast cancer (women age 60-69 years) Walker et al, 2014
Rectal bleeding 5.99% for colorectal cancer (men age 60-69 years)
3.50% for colorectal cancer (women age 60-69 years)
1.4% for colorectal cancer (age 40-69 years)
4.8% for colorectal cancer (age 70+ years)
1.8% for colorectal cancer (men age 15+ years)
1.5% for colorectal cancer (women age 15+ years)
Lawrenson et al, 2006
Hamilton et al, 2005a
Jones et al, 2007
Hemoptysis 2.4% for lung cancer (age 40+ years)
7.1% for lung cancer (age 70+ years)
5.8% for respiratory tract cancer (men age 15+ years)
3.3% for respiratory tract cancer (women age 15+ years)
Hamilton et al, 2005b
Jones et al, 2007
Hematuria (visible) 5.8% for urinary tract cancer (men age 15+ years)
3.3% for urinary tract cancer (women age 15+ years)
2.6% for bladder cancer (age 60+ years)
1.0% for kidney cancer (age 60+ years)
1.0% for prostate cancer (age 40+ years)
Jones et al, 2007
Shephard et al, 2012
Shephard et al, 2013
Hamilton et al, 2006
Postmenopausal bleeding 4.0% for endometrial cancer (age 55+ years)
4.6% for cervical cancer (age 55+ years)
Walker et al, 2013
Walker and Hamilton, 2017
Dysphagia 5.3% for esophageal cancer (men 15+ years)
2.1% for esophageal cancer (women age 15+ years)
4.8% for esophagogastric cancer (age 55+ years)
Jones et al, 2007
Stapley et al, 2013
Jaundice 21.6% for pancreatic cancer (age 60+ years) Stapley et al, 2012
Weight loss 1.2% for colorectal cancer (age 40+ years)
1.1% for lung cancer (age 40+ years)
0.9% for esophagogastric cancer (age 55+ years)
0.8% for pancreatic cancer (age 60+ years)
0.75% for prostate cancer (age 40+ years)
Hamilton et al, 2005a
Hamilton et al, 2005b
Stapley et al, 2013
Stapley et al, 2012
Hamilton et al, 2006
NOTE: All published positive predictive values increased with age. For further stratification of positive predictive values, refer to cited references.
Koo et al
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such as the African Women Awareness of CANcer tool
designed for breast and cervical cancer87 could support such
prioritization by identifying symptoms correlated with low
awareness.76,88,89 Symptoms associated with the longest
patient intervals (time from symptom onset to presentation)
may also be particularly worthy of targeting.90
PROMPT HELP-SEEKING FOR SYMPTOMS
Psychological, social, and cultural factors influence the
timeliness of help-seeking for symptoms.49,51,91,92 Individ-
ual- and group-level (eg, family or social network) barriers
include cancer fear and stigma, poor health literacy, lack of
trust in healthcare providers, and low expectations or per-
ceptions regarding healthcare access or quality.3,93-98 Such
barriers have been associated with demonstrably longer in-
tervals to help-seeking for possible cancer symptoms99,100
and advanced stage at diagnosis among those diagnosed
with cancer.101,102
System-wide factors also contribute to delayed presentation
and inequalities in cancer outcomes. These include the
proximity and accessibility of health care; the availability
of infrastructure and transport services; the direct costs of
seeking medical advice, diagnostic testing, and anticipated
treatment; and the indirect costs of seeking help includ-
ing travel and accommodation costs, care for dependents,
and time out of work.103-106 Addressing the individual and
system factors influencing prompt help-seeking is impor-
tant for improving equitable access to cancer services,
given that the above barriers are invariably more prevalent
in low-resource communities.
PROMPT INVESTIGATION AND DIAGNOSIS
Many additional steps lie between prompt help-seeking
for symptoms, the diagnosis of cancer, and the initiation
of treatment. Postpresentational intervals in LMICs often ac-
count for a greater proportion of total time to cancer diagnosis
and treatment compared with help-seeking intervals.98,107
Furthermore, focusing on early diagnosis is an important
precursor to establishing cancer screening programs by
increasing diagnostic capacity for all individuals with positive
results.108 Early diagnosis programs have the potential to
contribute to health system development as the diagnosis and
treatment of cancer requires a coordinated multidisciplinary
approach. The consideration of health system factors is
therefore critical for early diagnosis programs.12,109,110
Timely investigation and diagnosis of cancer relies on the
availability of medical equipment, imaging, pathology, and
clinical laboratory services. Increasing capacity for diag-
nostic technologies should be preceded by the consider-
ation of affordability and sustainability within the existing
health system infrastructure for the health system and
population.111 In England, the increasing volume of fast-
track referrals (Box 2) has added to pressures on secondary
care services such as colonoscopy provision and imaging,
pointing to the need for new technologies and interven-
tions to support risk management and clinical decision
making, including new service pathways.79,112 Fecal im-
munochemical testing, although initially introduced in the
context of bowel cancer screening, is increasingly con-
sidered as a sensitive triaging tool for patients presenting
with abdominal symptoms to manage demand for colo-
noscopy services.113-115 Access to and availability of timely
cancer treatment is also critical for early diagnosis to
contribute to cancer outcomes. In Zambia, decentralized
models of service provision that connect different levels
of care present an effective alternative to comprehensive
cancer centers, a common model of care in LMICs, while
repurposing existing care pathways (Box 3).118
Recruitment and retention of a skilled health workforce
including community health workers, specialists, and allied
health professionals (such as radiologists, pathologists,
and biomedical scientists) are also pivotal. Strengthening
knowledge and awareness of cancer signs and symptoms
among the healthcare workforce (particularly those
working in frontline services) is of equal, if not greater,
importance to raising awareness among the general
population.119-123
BOX 3. IMPLEMENTATION OF PRIMARY CARE–BASED BREAST CANCER SERVICES IN ZAMBIA
The majority of breast cancers in Zambia are currently diagnosed at stage III/IV, and early diagnosis has been identified as a
priority.116 Symptomatic individuals have to navigate multiple levels of the health system before diagnosis and treatment at the
national cancer care center in Lusaka. A national assessment of health services for breast and cervical cancer identified the
need for better coordination of early detection services for breast cancer.117
A breast cancer clinic was established at primary care level in a district hospital.118 Symptomatic women from surrounding
primary care facilities including rural health posts, health centers, and other district hospitals are assessed at the clinic.
Initially, an existing cervical cancer prevention program was used to direct eligible women for assessment and generate
awareness of the new service among primary care providers. The clinic provides timely diagnostic investigation (clinical
breast examination, same-visit ultrasound, and core- or fine-needle biopsy) and has surgical capacity. Patients requiring
chemotherapy or radiation are referred within 2 weeks to the national cancer care center. These decentralized care
pathways improved timeliness and access to diagnosis and treatment services by integrating provision with existing care
pathways.118 The intervention has been accompanied by workforce development, which was identified as a barrier to
cancer care delivery in Zambia.109
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Increasing health system capacity for timely cancer di-
agnosis and treatment relies on macro-level factors in-
cluding health system governance and financing.
Emigration of trained professionals to HICs may reduce
their availability in LMICs.124 Although strengthening
health systems can be challenging, creating or improving
clinical pathways for the diagnosis of cancer can provide
impetus and opportunities to improve healthcare delivery
for other nonmalignant diseases, collinear to the universal
healthcare agenda.108,124,125
DESIGNING AND EVALUATING EARLY DIAGNOSIS
PROGRAMS: CHALLENGES AND OPPORTUNITIES
Early diagnosis programs comprise complex interven-
tions, both acting on and being influenced by multiple
interplaying factors.12 The conceptual framework we pro-
pose aims to make the rationale of such interventions explicit
and in doing so support evidence-based strategies for
earlier diagnosis.
DESIGN AND IMPLEMENTATION
In settings with fragmented or nonexistent data infrastruc-
tures, population-specific health needs assessments prior
to the design and implementation of early diagnosis pro-
grams will require adaptation to available data. Neverthe-
less, systematically synthesizing up-to-date evidence to
inform intervention design remains challenging even where
routine data are readily available.55 In some instances, pri-
mary data collection may be a necessary component, using
instruments such as patient questionnaires and clinical
audit to identify existing barriers to early diagnosis.87,119,126
Incorporating implementation science can help identify
mechanisms that enable change or lead to improved out-
comes; it also helps to understand the role of contextual
influencers.127,128 The use of implementation science while
also embracing complexity and systems thinking can help to
tackle the gap between evidence and current practice.129-132
Measuring outcomes specific to implementation can inform
how best to adapt an intervention to real-life settings, deter-
mine effectiveness, and sustain and scale up efforts.127,133
The Behaviour Change Wheel128 and Normalization Pro-
cess Theory134 are some of the many theories and frame-
works that have been adopted to understand and assess
implementation in early cancer diagnosis programs in the
United Kingdom, Denmark, and Australia.135-140
MONITORING AND EVALUATION
Monitoring and evaluation are critical to the success of an
early diagnosis program.12 Early diagnosis programs target
changes in population-level behavior or health system
improvements, which can be difficult to quantify. For ex-
ample, symptom awareness campaigns may stimulate
transgenerational changes in attitudes toward cancer and
contribute to timely diagnosis later in the life course,141
whereas health system–wide changes may contribute to
broader improvements in healthcare delivery and help
streamline diagnostic pathways for cancer. Although some
randomized control trials have been conducted,120,142
the majority of early diagnosis programs are natural ex-
periments and so evaluations more often take other
forms such as before and after designs and interrupted
time series analysis, commonly involving mixed-methods
research.22,25,27,40,135,143-145
Process and outcome indicators for monitoring early di-
agnosis programs have been recommended by the
WHO.12 Measures should be selected based on available
resources and existing infrastructure, which will influence
their relative utility. For example, the proportion of pa-
tients with cancer diagnosed at early stage is often the
most direct outcome indicator but is contingent on reli-
able and accurate cancer registration services. The pa-
tient interval (time from symptom onset to help-seeking)
can be measured to evaluate possible improvements in
symptom awareness among patients with cancer; here,
audit methodologies or self-reported data may be more
informative than health records, which can often be
incomplete.146
Other metrics may be specific to certain intervention
types and health system contexts. For example, a range of
process and outcome measures have been examined for
the evaluation of the Be Clear on Cancer campaigns in
England.25 These include the cancer referral rate (the
number of urgent referrals for suspected cancer made by
primary care practices divided by the registered practice
population) and referral scheme sensitivity (the number
of cancer diagnoses resulting from an urgent referral,
rather than another route to diagnosis). The primary care
interval (time from first presentation in primary care to
referral to secondary care) has also been highlighted as a
measure of diagnostic timeliness in England, Scandi-
navia, and other countries50,147 but is of less relevance to
jurisdictions where patients may access specialist care
directly.
In conclusion, increasing cancer incidence globally com-
pels public health agencies to instigate cancer prevention
and control measures; early diagnosis programs in both
HIC and LMIC settings form a critical component. Cancer-
specific health needs assessment followed by the con-
sideration of symptom epidemiology can contribute to
priority setting within programs. Programs should also
consider societal and health system–level factors that in-
fluence prompt help-seeking, investigation, and diagnosis
of suspected cancer. The framework we propose can help
to identify population-specific evidence gaps and optimize
the design and evaluation of early diagnosis programs
contributing to global efforts for cancer control.
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